XFOR X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. (XFOR) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $210.8K.
Where they traded
Last open-market purchase: October 23, 2025 , by Craig Adam R .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Craig Adam R | Executive Chairman | Sell | 47,436 | $4.44 | $210.8K | 328,651 −12.6% of holding | |
| Volpone John | President | Sell | 24,576 | $4.44 | $109.2K | 265,305 −8.5% of holding | |
| KIRSKE DAVID | Chief Financial Officer | Sell | 8,543 | $4.26 | $36.4K | 167,750 −4.8% of holding | |
| KIRSKE DAVID | Chief Financial Officer | Sell | 16,961 | $4.29 | $72.8K | 176,293 −8.8% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.